Maria Halasz has been involved with biotechnology companies for 17 years; initially working in executive positions in biotechnology firms, then managing investment funds and later holding senior positions in corporate finance specialising in life sciences.Prior to joining Cellmid Ms Halasz had been an adviser to an independent sector based research firm in life sciences and managed Direct Capital Group Pty Ltd, a specialist biotechnology fund. She has also been a venture partner at the Emerging Technology Fund of venture capital firm Allen & Buckeridge.Since taking over as Chief Executive and Managing Director of Cellmid Ms Halasz has led the restructure of the business, the acquisition of the midkine intellectual property portfolio and the recapitalisation of the company.Ms Halasz is a Member of the Australian Institute of Company Directors and holds a science degree in Microbiology and an MBA.

Cellmid Limited (ASX:CDY) is a biotechnology company listed on the Australian Stock Exchange. The company is developing innovative therapies and diagnostic tests for heart attack, inflammatory diseases and cancer.Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine, an extensively validated therapeutic and diagnostic target in inflammation, autoimmunity and cancer.Cellmid is actively looking for partners to commercialise these significant midkine intellectual property assets in ischemia, cancer and inflammatory diseases.